title: Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.
abstract: Human papillomavirus (HPV) infection indicates favorable prognosis in oropharyngeal squamous cell carcinoma (SCC). The purpose of this study was for us to assess the impact of HPV in patients treated with sequential therapy versus concomitant chemoradiotherapy (CRT).
  
  
  
  Patients with stage III and IVA and B oropharyngeal SCC were reviewed spanning 10 years.
  
  
  
  Among 500 cases, 291 (58%) received CRT versus 209 (42%) sequential therapy. HPV status was known in 279 of patients (56%) and positive in 77% (determined by polymerase chain reaction [PCR; 91%], p16 immunohistochemical [IHC], or both). Median follow-up was 2.8 years. Overall survival (OS) did not differ for sequential therapy versus CRT overall (hazard ratio [HR] = 0.90; p = .66; 3-year OS = 86% and 87%) or within HPV-positive patients (HR = 0.89; p = .81; 3-year OS = 91% and 91%) or within HPV-negative patients (HR = 0.55; p = .32; 3-year OS = 85% and 75%).
  
  
  
  Survival for all patients was high and notable for HPV-negative patients treated with sequential therapy. Further studies in this patient population are warranted. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1618-E1624, 2016.
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Jochen H
authors.initials: JH
authors.lastname: Lorch
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Glenn J
authors.initials: GJ
authors.lastname: Hanna
authors.affiliation: Department of Medical Oncology, Mount Sinai School of Medicine, New York, New York.
authors.forename: Marshall R
authors.initials: MR
authors.lastname: Posner
authors.affiliation: Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Anne
authors.initials: A
authors.lastname: O'Neill
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Vijaya L
authors.initials: VL
authors.lastname: Thotakura
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Sewanti A
authors.initials: SA
authors.lastname: Limaye
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Guilherme
authors.initials: G
authors.lastname: Rabinowits
authors.affiliation: Department of Radiation Oncology, Rush Medical Center, Chicago, Illinois.
authors.forename: David J
authors.initials: DJ
authors.lastname: Sher
authors.affiliation: Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Roy B
authors.initials: RB
authors.lastname: Tishler
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Robert I
authors.initials: RI
authors.lastname: Haddad
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D008297:Male; D008875:Middle Aged; D009959:Oropharyngeal Neoplasms / Q000628:therapy* / Q000821:virology; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000628:therapy* / Q000821:virology; D011379:Prognosis; D012189:Retrospective Studies
keywords: cancer; chemotherapy; human papillomavirus (HPV); oropharyngeal; treatment